Bacterial Pneumonia and Pandemic Influenza Planning
Emerging Infectious Diseases·
- DOI
- 10.3201/eid1408.070751
- PMID
- 18680640
- PMCID
- PMC2600366
- OpenAlex
- W1986764425
- Study type
- Journal article
- Publisher
- Centers for Disease Control and Prevention (CDC)
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The article is relevant to pandemic preparedness policy because it addresses treatment planning for bacterial complications alongside antiviral and vaccine strategies. It also highlights potential differences in preparedness needs and expected benefits between developing and industrialized settings.
Structured evidence summary
Research question
The article examines how antimicrobial drug stockpiling, deployment, resistance surveillance, and pneumococcal vaccination could be incorporated into pandemic influenza planning, including in settings where antiviral drugs and vaccines may be less available.
Study design
This is a peer-reviewed journal article presenting a policy and planning discussion rather than an empirical population study.
Population and setting
The discussion concerns pandemic influenza preparedness globally, with particular attention to developing countries and comparisons with industrialized countries.
Main findings
The article identifies secondary bacterial pneumonia as an important consideration in pandemic preparedness and discusses antimicrobial stockpiles, resistance surveillance, and pneumococcal vaccination as components of response planning. It states that treating bacterial complications could provide greater benefits in developing countries where neuraminidase inhibitors and vaccines may be less affordable or available.
Public-health relevance
The article is relevant to pandemic preparedness policy because it addresses treatment planning for bacterial complications alongside antiviral and vaccine strategies. It also highlights potential differences in preparedness needs and expected benefits between developing and industrialized settings.
Important limitations
The supplied evidence does not state explicit study limitations, and the abstract does not provide empirical methods, participant details, or quantitative outcome estimates. This summary is therefore limited to the supplied single-article abstract and bibliographic metadata; the original paper is required for decision-grade interpretation.
GIDS interpretation
The article is discoverable in the supplied metadata under influenza, surveillance, vaccination, antimicrobial resistance, treatment, and health policy. Its content provides planning context only and does not establish or confirm a live surveillance signal.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 13 auditable classifier relationships to diseases, places, topics, and study design.